SuperworthMeiraGTx EPS MGTX
Diluted earnings per share by quarter and over the last twelve months, from 2017.
- Last 12 months, to Jun 30, 2026
- $0.71
- Latest quarter, Q2 FY26
- $1.71
- Fiscal year 2025
- −$1.42
MeiraGTx's earnings per share was $0.71 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was $1.71.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$1.42 | n/a |
| FY2024 | −$2.13 | n/a |
| FY2023 | −$1.57 | n/a |
| FY2022 | −$2.87 | n/a |
| FY2021 | −$1.81 | n/a |
| FY2020 | −$1.55 | n/a |
| FY2019 | −$1.70 | n/a |
| FY2018 | −$5.58 | n/a |
| FY2017 | −$3.71 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $1.71 | n/a | $0.71 | |
| Q1 FY26 | −$0.57 | n/a | −$1.48 | |
| Q4 FY25 | $0.19 | n/a | −$1.42 | |
| Q3 FY25 | −$0.62 | n/a | −$2.11 | |
| Q2 FY25 | −$0.48 | n/a | −$2.04 | |
| Q1 FY25 | −$0.51 | n/a | −$2.32 | |
| Q4 FY24 | −$0.50 | −256% | −$2.13 | |
| Q3 FY24 | −$0.55 | n/a | −$1.31 | |
| Q2 FY24 | −$0.76 | n/a | −$1.50 | |
| Q1 FY24 | −$0.32 | n/a | −$1.27 | |
| Q4 FY23 | $0.32 | n/a | −$1.57 | |
| Q3 FY23 | −$0.74 | n/a | −$2.47 |
Against its peers
Companies in Biotechnology nearest MeiraGTx's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| MGTXMeiraGTx | $0.71 | |
| VCELVericel | $0.46 | +283% a year |
| ADMAAdma Biologics | $0.70 | −18% a year |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| Peer median | $0.46 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on MeiraGTx
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.